• Age \> 18 years at the time of informed consent

• Histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC) as determined by a local laboratory (adenosquamous is also allowed).

• Tumor confined to the pancreas and deemed resectable or borderline resectable per NCCN guidelines for these criteria.

• Patients must have not received previous anti-cancer therapy for the treatment of pancreatic ductal adenocarcinoma.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

• Adequate organ function (laboratory results must be obtained within the 21-day screening window) including hematologic, renal and hepatic function.

‣ Absolute neutrophil count \> 1500/mm3

⁃ Platelets \> 100,000/mm3

⁃ Calculated creatinine clearance \> 60 mL/min (Cockcroft Gault)

⁃ Albumin \> 3.0 g/dL

⁃ Aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic pyruvic transaminase (SGPT) \< 3.0 x ULN

⁃ Total bilirubin ≤ 1.5 X ULN

• Able to adhere to study visit schedule and other protocol requirements

• Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study therapy

• Female subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile or abstain from heterosexual activity for the course of the study through 9 months after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \> 1 year